Managing ocular toxicities in myeloma

home / video-series / managing-ocular-toxicities-in-myeloma

Shaily Shah, MD, and Esen Karamursel Akpek, MD, discuss managing the potential ocular toxicities that can occur with belantamab mafodotin-blmf in patients with relapsed/refractory multiple myeloma, as well as the collaborative role between ophthalmologists and oncologists.

© 2024 MJH Life Sciences

All rights reserved.